Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director · President and CEO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,120,384 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Gift · Disposed 32,220 · Balance 2,120,384 F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund. F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | Direct | 296,833 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 296,833 F3: Includes 184,915 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F3: Includes 184,915 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 32,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001724310-26-000007 · wk-form4_1786740495.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,120,384 F1 · shares: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 35,198 | $16.50 | $580,767.00 |
DisclosureSEC source: 0001724310-26-000004 · wk-form4_1767907202.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,833 F1 · shares: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F2 · balance_after: Includes 184,915 Unvested RSUs. Read SEC document |
| January 03, 2026 Filed Jan 5, 2026 23:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 236,880 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001724310-26-000001 · wk-form4_1767656925.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,880 Underlying: Common Stock · 236,880 shares Expires 2036-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date Read SEC document |
| January 03, 2026 Filed Jan 5, 2026 23:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 78,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001724310-26-000001 · wk-form4_1767656925.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,031 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 184,915 Unvested RSUs. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 20:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724310-25-000005 · wk-form4_1757105029.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,152,604 F1 · shares: Reflects an in-kind charitable contribution of 50,000 shares of DNLI to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-25-000149 · wk-form4_1752268398.xml · derivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,369 Underlying: Common Stock · 40,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 455,282 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-25-000149 · wk-form4_1752268398.xml · derivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 622,809 Underlying: Common Stock · 455,282 shares Expires 2025-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 495,282 | $15.00 | $7,429,230.00 |
DisclosureSEC source: 0001714899-25-000149 · wk-form4_1752268398.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,071 F2 · kind: The sales reported by the Reporting Person were made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 09/16/2024. The shares sold primarily relate to 455,282 stock options that expire on 08/21/2025. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 177,940 Unvested RSUs. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 40,000 | $5.28 | $211,200.00 |
DisclosureSEC source: 0001714899-25-000149 · wk-form4_1752268398.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 748,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 177,940 Unvested RSUs. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 455,282 | $0.68 | $309,591.76 |
DisclosureSEC source: 0001714899-25-000149 · wk-form4_1752268398.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 177,940 Unvested RSUs. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 01:24 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,650 | $20.81 | $159,196.50 |
DisclosureSEC source: 0001714899-25-000049 · wk-form4_1736385877.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,071 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F3 · balance_after: Includes 177,940 Unvested RSUs. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:24 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 29,266 | $20.22 | $591,758.52 |
DisclosureSEC source: 0001714899-25-000049 · wk-form4_1736385877.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,721 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 177,940 Unvested RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 162,540 | $0.00 Strike: $21.26 | $0.00 |
DisclosureSEC source: 0001714899-25-000028 · wk-form4_1736294379.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,540 Underlying: Common Stock · 162,540 shares Expires 2035-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 54,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000028 · wk-form4_1736294379.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,987 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 192,940 Unvested RSUs. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-24-000206 · wk-form4_1729629050.xml · derivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,078,091 Underlying: Common Stock · 40,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 40,000 | $27.69 | $1,107,600.00 |
DisclosureSEC source: 0001714899-24-000206 · wk-form4_1729629050.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,807 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $27.49 to $28.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 197,200 Unvested RSUs. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 40,000 | $0.68 | $27,200.00 |
DisclosureSEC source: 0001714899-24-000206 · wk-form4_1729629050.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 197,200 Unvested RSUs. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,260 | $23.79 | $53,765.40 |
DisclosureSEC source: 0001714899-24-000197 · wk-form4_1724357777.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,807 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · balance_after: Includes 197,200 Unvested RSUs. Read SEC document |
| March 29, 2024 Filed Mar 29, 2024 21:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000097 · wk-form4_1711749539.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,202,604 F1 · shares: Reflects an in-kind charitable contribution of 40,000 shares of DNLI to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 02:15 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,589 | $17.29 | $165,793.81 |
DisclosureSEC source: 0001714899-24-000061 · wk-form4_1708049710.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,067 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price F3 · balance_after: Includes 202,200 RSUs. F4 · balance_after: Reflects 25,759 shares previously disclosed as held indirectly; but have been determined to be held directly. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 22:28 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,818 | $19.78 | $154,640.04 |
DisclosureSEC source: 0001714899-24-000039 · wk-form4_1705012085.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,268,363 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.60 to $20.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,483 | $19.43 | $339,694.69 |
DisclosureSEC source: 0001714899-24-000035 · wk-form4_1704846791.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,276,181 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.36 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 51,060 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 268,560 | $0.00 Strike: $20.33 | $0.00 |
DisclosureSEC source: 0001714899-24-000008 · wk-form4_1704495377.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,560 Underlying: Common Stock · 268,560 shares Expires 2034-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 89,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000008 · wk-form4_1704495377.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,957 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 221,897 RSU's as of January 4, 2024. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:32 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,309 | $22.59 | $52,160.31 |
DisclosureSEC source: 0001714899-23-000133 · wk-form4_1692822729.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,242,604 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: . The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.50 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 5,000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 2,526 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000123 · wk-form4_1692047595.xml · derivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,118,091 Underlying: Common Stock · 2,526 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,526 | $25.03 | $63,225.78 |
DisclosureSEC source: 0001714899-23-000123 · wk-form4_1692047595.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 18, 2022. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 2,526 | $0.68 | $1,717.68 |
DisclosureSEC source: 0001714899-23-000123 · wk-form4_1692047595.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,242,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Watts Family 2015 Trust. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:28 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000105 · wk-form4_1687300068.xml · derivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,120,617 Underlying: Common Stock · 50,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:28 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 50,000 | $31.40 | $1,570,000.00 |
DisclosureSEC source: 0001714899-23-000105 · wk-form4_1687300068.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:28 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 50,000 | $0.68 | $34,000.00 |
DisclosureSEC source: 0001714899-23-000105 · wk-form4_1687300068.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,289,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 24,800 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · derivative · entry 7 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,170,617 Underlying: Common Stock · 24,800 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the sharessubject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 24,800 | $25.15 | $623,720.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.36 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 24,800 | $0.68 | $16,864.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,264,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · derivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,195,417 Underlying: Common Stock · 200 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the sharessubject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 200 | $25.00 | $5,000.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 23:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 200 | $0.68 | $136.00 |
DisclosureSEC source: 0001714899-23-000066 · wf-form4_168237782624985.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,240,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000029 · wf-form4_167650567156375.xml · derivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,195,617 Underlying: Common Stock · 25,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 25,000 | $30.08 | $752,000.00 |
DisclosureSEC source: 0001714899-23-000029 · wf-form4_167650567156375.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.26 per share. Upon request by the Commission staff, the Issuer, or asecurityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 25,000 | $0.68 | $17,000.00 |
DisclosureSEC source: 0001714899-23-000029 · wf-form4_167650567156375.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,264,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,815 | $30.09 | $265,243.35 |
DisclosureSEC source: 0001714899-23-000029 · wf-form4_167650567156375.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,239,913 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.95 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 19,697 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 00:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000023 · wf-form4_167633361457163.xml · derivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,617 Underlying: Common Stock · 25,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The vesting of the shares subject to the option is contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on the date the closing price of Issuer's Common Stock equaled or exceeded $40.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018; and 50% of the shares subject to the option vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 00:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 25,000 | $29.10 | $727,500.00 |
DisclosureSEC source: 0001714899-23-000023 · wf-form4_167633361457163.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,229,031 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.75 to $29.57 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 00:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 25,000 | $0.68 | $17,000.00 |
DisclosureSEC source: 0001714899-23-000023 · wf-form4_167633361457163.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,254,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,433 | $30.59 | $105,015.47 |
DisclosureSEC source: 0001714899-23-000023 · wf-form4_167633361457163.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,229,031 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.39 to $30.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8,800 restricted stock units held by the Reporting Person F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 02:41 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,800 | $28.44 | $136,512.00 |
DisclosureSEC source: 0001714899-23-000013 · wf-form4_167331845186326.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,223,664 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15,000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,029 | $28.73 | $144,483.17 |
DisclosureSEC source: 0001209191-23-002179 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,213,464 F4 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.58 to $29.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15,500 RSUs held by the Reporting Person. F6 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 246,720 | $0.00 Strike: $27.63 | $0.00 |
DisclosureSEC source: 0001209191-23-002179 · doc4.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,720 Underlying: Common Stock · 246,720 shares Expires 2033-01-02 F7 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:07 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 82,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002179 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,934 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15,500 RSUs held by the Reporting Person. F3 · balance_after: Includes 231,934 RSUs. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,404 | $33.22 | $79,860.88 |
DisclosureSEC source: 0001714899-22-000129 · wf-form4_166128769265555.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,202,993 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.11 to $33.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 5,000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.